BioAge Labs, Inc (BIOA) Income Statement
BIOA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBIOA revenue and net income
Where BIOA's revenue goes
2025Each bar shows an amount and its share of revenue. BIOA kept −896.1% of revenue as net income.
BIOA profit margins
BIOA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | +1.7% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BIOA quarterly EPS vs estimates
BioAge Labs beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.68).
BIOA income statement
| 2025 | 2024 | 2023 | 2022 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $0 | $0 | $0 | $14.9M | $8.3M | $2.2M | $1.5M | $2.7M |
| Cost of revenue | $213,000 | — | — | — | $22.3M | $13.7M | $2.6M | $6.0M | $2.7M |
| Gross profit | $9.0M | — | — | — | −$7.4M | −$5.4M | −$440,828 | −$4.5M | −$23,782 |
| Research & development | $74.0M | $59.0M | $33.9M | $30.5M | $5.5M | $7.2M | $20.3M | $15.2M | $16.6M |
| Sales, general & admin | $27.8M | $19.2M | $14.5M | $9.4M | $12.4M | $9.5M | $10.6M | $10.7M | $9.8M |
| Total operating expenses | $101.8M | $78.2M | $48.4M | $40.0M | $102.6M | $24.2M | $38.1M | $30.7M | $41.2M |
| Operating income | −$92.8M | −$78.2M | −$48.4M | −$40.0M | −$110.0M | −$29.6M | −$38.5M | −$35.2M | −$41.2M |
| Interest income | $13.1M | $9.6M | $2.4M | $465,000 | — | — | — | — | — |
| Interest expense | $697,000 | $2.4M | $7.8M | $241,000 | — | — | — | — | $7.4M |
| Income before taxes | −$80.6M | −$71.1M | −$63.9M | −$39.7M | −$102.1M | −$28.3M | −$41.2M | −$47.2M | −$33.7M |
| Income taxes | — | −$71.1M | $7.8M | $241,000 | $81,735 | $25,646 | −$3,786 | $75,371 | $102,794 |
| Net income | −$80.6M | −$71.1M | −$63.9M | −$39.7M | −$98.2M | −$22.5M | −$37.2M | −$46.4M | −$33.2M |
| EBITDA | −$79.7M | −$68.6M | −$55.9M | −$39.4M | −$88.7M | −$13.3M | −$33.1M | −$45.0M | −$38.8M |
| EPS (diluted) | −$2.24 | −$8.30 | −$1.87 | — | −$2.34 | −$0.66 | −$1.32 | −$1.65 | −$1.18 |
| Gross margin | 100.0% | — | — | — | −49.4% | −65.2% | −20.3% | −291.7% | −0.9% |
| Operating margin | −1,031.5% | — | — | — | −736.2% | −358.2% | −1,773.9% | −2,281.5% | −1,545.1% |
| Net margin | −896.1% | — | — | — | −656.8% | −271.7% | −1,713.9% | −3,008.5% | −1,246.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.8M | $3.1M | $2.1M | $2.4M | $1.5M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $63,000 | $69,000 | $0 | $58,000 | $0 | — | — | — | — | — | — |
| Gross profit | $2.5M | $2.7M | $3.1M | $2.1M | $2.4M | $1.5M | — | — | — | — | — | — |
| Research & development | $24.4M | $20.4M | $24.5M | $18.5M | $19.8M | $11.1M | $19.2M | $20.0M | $10.5M | $9.3M | $10.1M | $6.5M |
| Sales, general & admin | $7.4M | $7.8M | $7.0M | $6.7M | $7.3M | $6.8M | $6.1M | $4.7M | $4.8M | $3.5M | $3.5M | $3.4M |
| Total operating expenses | $31.8M | $28.1M | $31.5M | $25.2M | $27.2M | $17.9M | $25.4M | $24.8M | $15.3M | $12.8M | $13.6M | $9.9M |
| Operating income | −$29.3M | −$25.4M | −$28.4M | −$23.1M | −$24.8M | −$16.4M | −$25.4M | −$24.8M | −$15.3M | −$12.8M | −$13.6M | −$9.9M |
| Interest income | $3.4M | $3.3M | $2.8M | $3.2M | $3.4M | $3.7M | $4.1M | $2.0M | $2.2M | $1.3M | $379,000 | $499,000 |
| Interest expense | $1,000 | $39,000 | $92,000 | $149,000 | $201,000 | $255,000 | $319,000 | $388,000 | $443,000 | $1.2M | $2.6M | $2.4M |
| Income before taxes | −$26.1M | −$22.3M | −$25.9M | −$20.2M | −$21.6M | −$12.9M | −$21.1M | −$23.4M | −$13.6M | −$13.0M | −$21.0M | −$14.6M |
| Income taxes | — | — | — | — | — | — | — | — | $443,000 | $1.2M | — | — |
| Net income | −$26.1M | −$22.3M | −$25.9M | −$20.2M | −$21.6M | −$12.9M | −$21.1M | −$23.4M | −$13.6M | −$13.0M | −$21.0M | −$14.6M |
| EBITDA | −$26.0M | −$22.2M | −$25.8M | −$20.0M | −$21.3M | −$12.6M | −$20.8M | −$23.0M | −$13.1M | −$11.7M | −$18.4M | −$12.2M |
| EPS (diluted) | −$0.58 | −$0.52 | −$0.72 | −$0.56 | −$0.60 | −$0.36 | −$1.00 | −$6.70 | −$0.60 | — | — | — |
| Gross margin | 100.0% | 97.7% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating margin | −1,196.8% | −915.4% | −923.4% | −1,126.6% | −1,027.0% | −1,133.4% | — | — | — | — | — | — |
| Net margin | −1,064.7% | −802.8% | −842.9% | −982.0% | −894.0% | −891.0% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BIOA's financial statements (latest annual report filed March 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BIOA financial results
In fiscal year 2025 (ended December 31, 2025), BioAge Labs reported revenue of $9.0 million. It had a net loss of $80.6 million, a net profit margin of −896.1%. Diluted earnings per share came to −$2.24. Over five years revenue grew at an average rate of 1.7% a year.
See the BIOA stock overview for the latest quote and news, or the BIOA chart for price history and technical indicators.
BIOA income statement FAQ
What is BioAge Labs's annual revenue?
BioAge Labs reported total revenue of $9.0 million for fiscal year 2025, which ended on December 31, 2025.
Is BioAge Labs profitable?
No. BioAge Labs reported a net loss of $80.6 million in fiscal 2025, a net profit margin of −896.1%; its operating margin was −1,031.5%.
What is BioAge Labs's gross margin?
BioAge Labs's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, BioAge Labs kept $100 after the direct cost of its products and services.
How much does BioAge Labs spend on research and development?
BioAge Labs spent $74.0 million on research and development in fiscal 2025, 822.3% of revenue.
How fast is BioAge Labs growing?
Revenue grew 1.7% a year on average over the last five fiscal years, from $8.3 million to $9.0 million.
What are BioAge Labs's earnings per share?
BioAge Labs earned $-2.24 per diluted share in fiscal 2025, compared with $-8.30 a year earlier.
When will BioAge Labs report its next earnings?
BioAge Labs is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does BioAge Labs's fiscal year end?
BioAge Labs's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 24, 2026.